Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415310 | 0.77 | MEN1 (0.31) | MEN1GAAKMT2AL3MBTL1 | |
| SCHEMBL3336864 | 0.77 | USP2 (0.31) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7950262 | 0.74 | USP2 (0.30) | SMN1; SMN2 | |
| SCHEMBL16873391 | 0.74 | — | — | |
| SCHEMBL13461228 | 0.72 | — | — | |
| SCHEMBL18413765 | 0.72 | KEAP1 (0.38) | KEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL737735 | 0.72 | — | — | |
| SCHEMBL158419 | 0.71 | USP2 (0.41) | SMN1; SMN2 | |
| SCHEMBL20279957 | 0.70 | — | — | |
| SCHEMBL17526051 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928833-B1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| EP-1928833-A1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007039220-A1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | CNR2, CNR1, GPR52 | MEN1 3734/4885GAA 4132/4885KMT2A 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.